Kintsugi Therapeutics

Kintsugi Therapeutics is a preclinical-stage biotechcompany developing a first-in-class treatment for NASH.

Sector

Biotech

Stage

Prototyping, preclinical

Country

Spain


First-in-class treatment for NASH

Triple mechanism of action inhibitors (lipogenesis, apoptosis and inflammation).

Patented Technology

Status

Pending

IP Type

Patent

Time

Countries

Australia
Austria
Belgium
Canada
China
Denmark
Finland
France
Germany
Israel
Italy
Japan
Netherlands
Russia
South Korea
Spain
Switzerland
USA
United Kingdom

Coverage

Our patents is a composition of matter patent that protects the structure of our inhibitors.

Know more of this patent

This information is confidential, do not share or copy.

Under evaluation at least till: 15th of September

If you want to have more information or you want to review the project, you have to login or register

KEEP REVIEWING

©2021 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar